Eptifibatide
Overview
Eptifibatide is an antiplatelet drug that inhibits glycoprotein II b/ III a. Eptifibatide is used intravenously in the management of unstable angina and in patients undergoing angioplastic coronary interventions. In the latter case, the events of myocardial infarction or death have been reduced to 20%.
Categories
- 10 Drugs affecting the blood
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Eptifibatide's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 180 mcg/kg | 180 (180) | As recommended. | IV | This loading dose of is given over 1 to 2 minutes immediately after diagnosis, followed by continuous i.v.-infusion of 2µg/kg and minute until either hospital discharge or initiation of coronary artery bypass grafting, or for up to 72 hours. At least 4 hours before discharge all local or systemic bleedings should have been controlled and terminated. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Eptifibatide is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Eptifibatide is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Eptifibatide
Back to top
Previous Drug Generic - Next Drug Generic